RecruitingEarly Phase 1NCT04532489

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)

Sponsor

Benjamin Viglianti

Enrollment

6 participants

Start Date

Jan 18, 2021

Study Type

INTERVENTIONAL

Conditions

Hypertension Cholesterol Radiotracer

Summary

This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \[18F\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a new PET scan imaging agent called [18F]FNP-59, which tracks how cholesterol moves through the adrenal glands, to understand how much radiation it exposes the body to in healthy volunteers. **You may be eligible if...** - You are a healthy adult with no known adrenal gland problems - You are willing to undergo PET scan imaging - You weigh under 400 lbs (181 kg) - You are able to provide your own consent **You may NOT be eligible if...** - You are pregnant - You are unable to undergo imaging - You are a prisoner - You currently use steroids, oral contraceptives, spironolactone, estrogen, androgen, progesterone, ACE inhibitors, or ARBs - You have a known adrenal gland condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.